Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
antihemophilic factor-von Willebrand factor
antihemophilic factor-von Willebrand factor
- Formulary
- Restricted
- Therapeutic Interchange
Last updated: Apr. 17, 2020
Hemophilia Blood Factor Flow Diagram
Alphanate is formulary unrestricted.
Humate-P is restricted to ‘no substitution’ orders. Interchange Humate-P orders to Alphanate.
If not specified, the Physician must be contacted to determine specific indication and dose of Alphanate.
Human-plasma derived von Willebrand factor (contains factor VIII) [ALPHANATE,HUMATE-P] can be dosed based on either the Factor VIII or VWF component.
Diagnosis should be confirmed to determine appropriate dosing unit:
Diagnosis
Preferred Dosing Unit
Hemophilia A (Factor VIII Defiency)
von Willebrand disease (VWD)
VWF:RCo international units
Factor VIII may be used to guide dosing for either disease state. In general, the treatment of von Willenbrand disease requires higher doses (units/kg) of Factor VIII component compared to the treatment of Hemophilia A.
Standard Ratios
The ratio of VWF:RCo to FVIII in ALPHANATE varies by lot, so dispensed dose should be from product currently in stock.
VWF:RCo activity will not be less than 0.4 VWF:RCo IU per 1 IU of FVIII:C
HUMATE-P has an average ratio of 2.4 VWF:RCo IU to 1 IU of FVIII. However, the dispensed dose should be based on product currently in stock.
Reviewed: 24 April 2018